Overview
Dr. Arpita Maniar joined the Duke Eye Center as Assistant Professor of Ophthalmology in September 2023. She is a part of the division of ocular oncology, and is fellowship-trained in both ocular oncology and oculoplastic surgery.
Dr. Maniar provides comprehensive care for a wide variety of benign and malignant tumors affecting the eye and its surrounding structures, across all age groups. This includes more common ocular tumors like melanoma, lymphoma, ocular metastasis and retinoblastoma to eyelid tumors like squamous cell carcinoma and basal cell carcinoma, to less common and rare orbital and ocular surface tumors. She also manages ocular side-effects from systemic chemotherapeutic drugs. She often collaborates with other specialists from radiation oncology, interventional radiology, medical oncology ,ENT and neurosurgery to deliver comprehensive cancer care.
Her research interests lay in studying ocular melanomas and retinoblastomas. She has published several peer-reviewed journal articles and book chapters on these conditions, and has also delivered talks at regional, national and international conferences. Dr. Maniar is a member of the American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, and All India Ophthalmological Society.
Dr. Maniar’s commitment to effective communication and individualized care is a fundamental aspect of her practice.
Current Appointments & Affiliations
Recent Publications
Optic nerve sheath meningiomas harbor distinct genetic variants.
Journal Article Am J Clin Pathol · January 5, 2026 OBJECTIVE: Both primary optic nerve sheath meningiomas (pONSMs) and secondary optic nerve sheath meningiomas (sONSMs) pose clinical challenges because standard treatments such as surgical debulking and radiation therapy can further damage the optic nerve, ... Full text Link to item CiteComparison of single- versus multi-drug treatment for intra-arterial chemotherapy (IAC) in children with retinoblastoma.
Journal Article Interv Neuroradiol · March 26, 2025 ObjectiveIntra-arterial chemotherapy (IAC) is a well-established treatment for retinoblastoma (RB). However, there are no standardized recommendations regarding the choice of drugs. This study compares the outcomes of single- versus multi-drug therapy.Meth ... Full text Link to item CiteYttrium-90 (90Y) brachytherapy for squamous carcinoma: Treatment of the conjunctiva, cornea, and sclera.
Journal Article Am J Ophthalmol Case Rep · December 2024 PURPOSE: Patients with conjunctival squamous cell carcinoma that present with persisting disease or recurrence following topical chemotherapy and/or surgery especially when invading the sclera are challenging to treat. Herein, we describe the use of high-d ... Full text Link to item CiteRecent Grants
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma
Clinical TrialCo-Principal Investigator · Awarded by Aura Biosciences, Inc. · 2024 - 2029View All Grants